Results 21 to 30 of about 3,492 (143)

Disrupting the CBFβ-SMMHC-RUNX1 oncogenic protein–protein interaction in inv(16) AML: from fusion biology to targeted therapy [PDF]

Discover Oncology
Core-binding factor (CBF) leukemias, including inv(16) AML, involve RUNX1/CBFβ chromosomal rearrangements that generate oncogenic fusion proteins. In inv(16) AML, the CBFβ–SMMHC fusion (CBFB–MYH11) dominantly perturbs RUNX1 by sequestering it in aberrant,
Emadeldin M. Kamel, Sally Mostafa Khadrawy, Mohamed A. M. Ali, Noha A. Ahmed, Saleh Alkhedhairi, Faris F. Aba Alkhayl, Al Mokhtar Lamsabhi   +6 more
doaj   +2 more sources

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine [PDF]

Blood Cancer Journal
Ting Shi, Ruicong Xue, Jing Jia, Menghan Liu, Yalan Zhou, Chuanying Geng, Yuan Jian, Ying Tian, Yanru Zhang, Wenjing Li, Lefu Huang, Huixing Zhou, Aijun Liu, Wen Gao, Wenming Chen, Yun Leng, Yin Wu, Hong-Hu Zhu   +17 more
doaj   +2 more sources

Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.

Blood, 2017
Key Points CHD7 interacts with CBFβ-SMMHC through RUNX1 and modulates their gene expression regulation. CHD7 is important for CBFB-MYH11 leukemogenesis in the mouse model.
Zhen T, Kwon EM, Zhao L, Hsu J, Hyde RK, Lu Y, Alemu L, Speck NA, Liu PP.   +8 more
europepmc   +2 more sources

<i>CBFB::MYH11</i> Fusion Located on a Supernumerary Ring Chromosome 16 in Pediatric Acute Myeloid Leukemia: Diagnostic Challenges and Prognostic Implications. [PDF]

Genes (Basel)
We report a unique pediatric acute myeloid leukemia (AML) case characterized by a CBFB::MYH11 fusion located on a supernumerary ring chromosome 16. Following diagnosis through comprehensive blood and bone marrow assays, the patient was enrolled in the ...
Xia C, Acquazzino M, Althof PA, Nelson M, Harris RA, Spaulding JR, Khoury JD, Tang Z.   +7 more
europepmc   +2 more sources

AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome

Hematology, 2022
Objectives Acute myeloid leukemia (AML) with inv(16)/t(16;16) is among the most frequent AML subtypes. It is recognized by the detection of the CBFB-MYH11 fusion which confers a favorable prognosis, irrespective of the presence of secondary cytogenetic ...
Nada Assaf, Christine Lefebvre, Victoria Raggueneau, Geoffroy Guignedoux, Alice Marceau-Renaut, Simon Chevalier, Sylvie Tondeur, Dominique Bories, Riad Benramdane, Philippe Rousselot, Christine Terré   +10 more
doaj   +1 more source

Acute myeloid leukemia with inv(16)(p13.1q22) and deletion of the 5’MYH11/3’CBFB gene fusion: a report of two cases and literature review

Molecular Cytogenetics, 2020
Background Abnormalities of chromosome 16 are found in about 5–8% of acute myeloid leukemia (AML). The AML with inv(16)(p13.1q22) or t (16;16)(p13.1;q22) is associated with a high rate of complete remission (CR) and favorable overall survival (OS) when ...
Lili Lv, Jingwei Yu, Zhongxia Qi
doaj   +1 more source

Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance

Nature Communications, 2021
miR-126 is highly expressed in inv(16) Acute myeloid leukemia (AML) but its role is unclear. Here, the authors show that the aberrant expression of miR-126 in inv(16) AML is directly due to the CBFB-MYH11 fusion gene and that it can promote AML ...
Lianjun Zhang, Le Xuan Truong Nguyen, Ying-Chieh Chen, Dijiong Wu, Guerry J. Cook, Dinh Hoa Hoang, Casey J. Brewer, Xin He, Haojie Dong, Shu Li, Man Li, Dandan Zhao, Jing Qi, Wei-Kai Hua, Qi Cai, Emily Carnahan, Wei Chen, Xiwei Wu, Piotr Swiderski, Russell C. Rockne, Marcin Kortylewski, Ling Li, Bin Zhang, Guido Marcucci, Ya-Huei Kuo   +24 more
doaj   +1 more source

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

Haematologica, 2020
Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for 2 years after ...
Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid, Aaron D. Schimmer   +15 more
doaj   +1 more source

BAALC-Expressing Leukemia Hematopoietic Stem Cells and Their Place in the Study of CBF-Positive Acute Myeloid Leukemias in Children and Adults

Клиническая онкогематология, 2023
Background. Due to changing views on pathogenesis, risk factors and therapy strategies in prognostically favorable CBF-positive acute myeloid leukemias[1] (AML), the expression monitoring of RUNX1/RUNX1T1 or CBFB/MYH11 fusion genes, as an additional ...
M. M. Kanunnikov, Nikolai Nikolaevich Mamaev, T. L. Gindina, A. I. Shakirova, A. M. Sadykov, S. V. Razumova, S. N. Bondarenko, L. S. Zubarovskaya   +7 more
doaj   +1 more source

Detección del gen de fusión CBFB-MYH11/INV (16) en paciente con leucemia aguda mielomonocítica [PDF]

, 2020
Context: Acute myelomonocytic leukemia is an acute myeloid leukemia subtype due to the inversion of chromosome 16 that causes the formation of a fusion gene called CBFB-MYH11 Objective: Detecting the existence of this fusion gene is critical in the ...
Arcentales-Cayamcela, Mauro Javier, Chiang-Wong, Héctor, Campoverde-Cisneros, Manuel Alfredo   +2 more
core   +1 more source